Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals.
Mellors J. et al, (2025), Nature communications, 16
Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial
Jenkin D. et al, (2025), The Lancet Microbe, 101022 - 101022
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial
Conlin K. et al, (2025), Vaccine, 45, 126582 - 126582
Translational science at the undergraduate level: awakening talents to overcome the valley of death - case report
Ferreira Jr. RS. et al, (2025), Journal of Venomous Animals and Toxins including Tropical Diseases, 31
Ebola disease: bridging scientific discoveries and clinical application.
Rojek A. et al, (2024), The Lancet. Infectious diseases
Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model.
O'Donnell KL. et al, (2024), International journal of molecular sciences, 25
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.
Costa Clemens SA. et al, (2024), The Lancet. Microbe
Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.
Flaxman A. et al, (2024), PLoS pathogens, 20
Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine.
Bissett C. et al, (2024), NPJ vaccines, 9
Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease
Drury RE. et al, (2024), Nature Communications, 15
A bivalent Adenovirus-Vectored Vaccine induces a robust humoral response, but does not protect cynomolgus macaques against a lethal challenge with Sudan virus.
van Tol S. et al, (2024), The Journal of infectious diseases
Serological cross-reactivity between Crimean-Congo haemorrhagic fever virus and Nairobi sheep disease virus glycoprotein C.
Maze EA. et al, (2024), Frontiers in immunology, 15
ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface.
Ni T. et al, (2023), iScience, 26
Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters.
Port JR. et al, (2023), Nature communications, 14
Proficiency tests to evaluate the impact on assay outcomes of harmonized influenza-specific Intracellular Cytokine Staining (ICS) and IFN-ɣ Enzyme-Linked ImmunoSpot (ELISpot) protocols.
Waerlop G. et al, (2023), Journal of immunological methods, 523
Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination.
Mitsi E. et al, (2023), Nature communications, 14
Generation and Characterisation of Monoclonal Antibodies against Nairobi Sheep Disease Virus Nucleoprotein.
Maze EA. et al, (2023), Viruses, 15